Literature DB >> 31122919

Susceptibility-Weighted MR Imaging Hypointense Rim in Progressive Multifocal Leukoencephalopathy: The End Point of Neuroinflammation and a Potential Outcome Predictor.

M M Thurnher1, J Boban2, A Rieger3, E Gelpi4,5.   

Abstract

BACKGROUND AND
PURPOSE: Progressive multifocal leukoencephalopathy (PML) represents a life-threatening demyelinating disorder of the brain caused by reactivation of a rare opportunistic infection with JC Polyomavirus. The aims of this study were to describe the incidence of a susceptibility-weighted imaging hypointense rim in patients with multifocal leukoencephalopathy and to explore the histologic correlates and prognostic value of the rim with regard to the clinical outcome.
MATERIALS AND METHODS: This retrospective study included 18 patients with a definite diagnosis of progressive multifocal leukoencephalopathy. Ten patients were HIV-positive, 3 patients had natalizumab-associated progressive multifocal leukoencephalopathy, 1 patient had multiple myeloma, 3 patients had a history of lymphoma, and 1 was diagnosed with acute myeloid leukemia. Patients were divided into short- (up to 12 months) and long-term (>12 months) survivors. A total of 93 initial and follow-up MR imaging examinations were reviewed. On SWI, the presence and development of a hypointense rim at the periphery of the progressive multifocal leukoencephalopathy lesions were noted. A postmortem histologic examination was performed in 2 patients: A rim formed in one, and in one, there was no rim.
RESULTS: A total of 73 progressive multifocal leukoencephalopathy lesions were observed. In 13 (72.2%) patients, a well-defined thin, linear, hypointense rim at the periphery of the lesion toward the cortical side was present, while in 5 (27.8%) patients, it was completely absent. All 11 long-term survivors and 2 short-term survivors presented with a prominent SWI-hypointense rim, while 5/7 short-term survivors did not have this rim.
CONCLUSIONS: The thin, uniformly linear, gyriform SWI-hypointense rim in the paralesional U-fibers in patients with definite progressive multifocal leukoencephalopathy might represent an end-point stage of the neuroinflammatory process in long-term survivors.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2019        PMID: 31122919     DOI: 10.3174/ajnr.A6072

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  4 in total

1.  A comparative study of multimodal magnetic resonance in the differential diagnosis of acquired immune deficiency syndrome related primary central nervous system lymphoma and infection.

Authors:  Jingjing Li; Ming Xue; Shuo Yan; Chunshuang Guan; Ruming Xie; Budong Chen
Journal:  BMC Infect Dis       Date:  2021-02-10       Impact factor: 3.090

Review 2.  MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily practice.

Authors:  Mio Sakai; Masahiro Higashi; Takuya Fujiwara; Tomoko Uehira; Takuma Shirasaka; Katsuyuki Nakanishi; Nobuo Kashiwagi; Hisashi Tanaka; Hitoshi Terada; Noriyuki Tomiyama
Journal:  Jpn J Radiol       Date:  2021-06-14       Impact factor: 2.374

Review 3.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937

4.  Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.

Authors:  Manel Alleg; Morgane Solis; Seyyid Baloglu; François Cotton; Philippe Kerschen; Bertrand Bourre; Guido Ahle; Jean-Pierre Pruvo; Xavier Leclerc; Patrick Vermersch; Caroline Papeix; Élisabeth Maillart; Caroline Houillier; Cécile Moluçon Chabrot; Béatrice Claise; Sandra Malak; Guillaume Martin-Blondel; Fabrice Bonneville; Alexis Caulier; Jean-Pierre Marolleau; Jérôme Tamburini Bonnefoy; Philippe Agape; Céline Kennel; Xavier Roussel; Adrien Chauchet; Jérôme De Seze; Samira Fafi-Kremer; Stéphane Kremer
Journal:  Eur Radiol       Date:  2020-11-06       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.